International Stem Cell Corp (PK:ISCO)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 5950 Priestly Dr
CARLSBAD CA 92008-8849
Tel: N/A
Website: https://www.internationalstemcell.com
IR: See website
<
Key People
Andrey Semechkin
Co-Chairman of the Board, Chief Executive Officer
Donald Arthur Wright
Independent Co-Chairman of the Board, CEO and President of SIS, Inc.
Russell Kern
Executive Vice President, Chief Scientific Officer
Business Overview
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
Financial Overview
For the fiscal year ended 31 December 2023, International Stem Cell Corp revenues decreased 5% to $7.8M. Net loss decreased 60% to $131K. Revenues reflect Biomedical market segment decrease of 4% to $6.9M, Anti-aging cosmetic market segment decrease of 12% to $923K. Lower net loss reflects Anti-aging cosmetic market segment loss decrease of 7% to $519K.
Employees: 29 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $6.97M as of Dec 31, 2023
Annual revenue (TTM): $7.79M as of Dec 31, 2023
EBITDA (TTM): -$0.47M as of Dec 31, 2023
Net annual income (TTM): -$0.13M as of Dec 31, 2023
Free cash flow (TTM): $0.85M as of Dec 31, 2023
Net Debt Last Fiscal Year: $1.87M as of Dec 31, 2023
Shares outstanding: 8,004,389 as of Mar 25, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.